Douglass Winthrop Advisors’s Merck MRK Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$35.2M Sell
292,328
-15,002
-5% -$1.73M 0.64% 36
2025
Q4
$32.3M Sell
307,330
-1,597
-0.5% -$150K 0.57% 35
2025
Q3
$25.9M Buy
308,927
+25,337
+9% +$2.09M 0.45% 36
2025
Q2
$22.4M Sell
283,590
-12,143
-4% -$965K 0.41% 34
2025
Q1
$26.5M Sell
295,733
-19,726
-6% -$1.84M 0.51% 35
2024
Q4
$31.4M Sell
315,459
-13,284
-4% -$1.37M 0.61% 34
2024
Q3
$37.3M Sell
328,743
-8,075
-2% -$959K 0.71% 35
2024
Q2
$41.7M Sell
336,818
-90,149
-21% -$11.6M 0.85% 34
2024
Q1
$56.3M Buy
426,967
+22,151
+5% +$2.73M 1.16% 30
2023
Q4
$44.1M Buy
404,816
+5,112
+1% +$531K 0.99% 33
2023
Q3
$41.1M Sell
399,704
-13,673
-3% -$1.47M 1.02% 33
2023
Q2
$47.7M Sell
413,377
-2,631
-0.6% -$299K 1.14% 33
2023
Q1
$44.3M Sell
416,008
-6,403
-2% -$691K 1.15% 31
2022
Q4
$46.9M Buy
422,411
+30,562
+8% +$3.12M 1.28% 31
2022
Q3
$33.7M Sell
391,849
-7,080
-2% -$632K 1.02% 32
2022
Q2
$36.4M Sell
398,929
-23,116
-5% -$2.05M 1.02% 33
2022
Q1
$34.6M Sell
422,045
-79,018
-16% -$6.23M 0.82% 33
2021
Q4
$38.4M Sell
501,063
-847,416
-63% -$67.5M 0.86% 33
2021
Q3
$101M Buy
1,348,479
+6,725
+0.5% +$511K 2.48% 14
2021
Q2
$104M Sell
1,341,754
-164,850
-11% -$12.3M 2.56% 12
2021
Q1
$111M Buy
1,506,604
+465,372
+45% +$34.3M 2.97% 8
2020
Q4
$81.3M Buy
1,041,232
+220,399
+27% +$16.9M 2.32% 19
2020
Q3
$65M Buy
820,833
+628,554
+327% +$49.2M 2.11% 21
2020
Q2
$14.2M Buy
192,279
+41,620
+28% +$3.13M 0.53% 37
2020
Q1
$11.1M Sell
150,659
-3,291
-2% -$259K 0.5% 35
2019
Q4
$13.4M Sell
153,950
-5,639
-4% -$463K 0.47% 36
2019
Q3
$12.8M Sell
159,589
-7,234
-4% -$580K 0.49% 37
2019
Q2
$13.3M Sell
166,823
-6,838
-4% -$524K 0.54% 37
2019
Q1
$13.8M Sell
173,661
-11,287
-6% -$844K 0.6% 38
2018
Q4
$13.5M Buy
184,948
+10,811
+6% +$763K 0.67% 39
2018
Q3
$11.8M Sell
174,137
-121,668
-41% -$7.75M 0.52% 40
2018
Q2
$17.1M Sell
295,805
-15,647
-5% -$883K 0.77% 40
2018
Q1
$16.2M Buy
311,452
+1,399
+0.5% +$75.6K 0.79% 37
2017
Q4
$16.6M Sell
310,053
-4,691
-1% -$260K 0.91% 34
2017
Q3
$19.2M Sell
314,744
-13,511
-4% -$819K 1.12% 33
2017
Q2
$20.1M Sell
328,255
-23,077
-7% -$1.4M 1.22% 31
2017
Q1
$21.3M Sell
351,332
-11,428
-3% -$693K 1.33% 29
2016
Q4
$20.4M Buy
362,760
+630
+0.2% +$36.9K 1.37% 30
2016
Q3
$21.6M Sell
362,130
-7,130
-2% -$417K 1.49% 30
2016
Q2
$20.3M Sell
369,260
-18,338
-5% -$976K 1.43% 31
2016
Q1
$19.6M Sell
387,598
-2,799
-0.7% -$137K 1.41% 29
2015
Q4
$19.7M Buy
390,397
+12,170
+3% +$614K 1.46% 25
2015
Q3
$17.8M Sell
378,227
-615
-0.2% -$32.7K 1.41% 27
2015
Q2
$20.8M Hold
378,842
1.61% 24
2015
Q1
$20.8M Buy
378,842
+67,602
+22% +$3.83M 1.61% 24
2014
Q4
$16.9M Buy
311,240
+1,558
+0.5% +$86.8K 1.5% 25
2014
Q3
$17.5M Sell
309,682
-1,451
-0.5% -$81.5K 1.62% 25
2014
Q2
$17.2M Sell
311,133
-11,124
-3% -$607K 1.58% 26
2014
Q1
$17.5M Sell
322,257
-1,593
-0.5% -$82.5K 1.72% 25
2013
Q4
$15.5M Sell
323,850
-4,039
-1% -$185K 1.61% 25
2013
Q3
$14.9M Buy
327,889
+26,334
+9% +$1.2M 1.73% 23
2013
Q2
$13.4M Buy
+301,555
New +$13.5M 1.62% 26

Other funds holding MRK

Douglass Winthrop Advisors's MRK Position: Q1 2026 in Review

Douglass Winthrop Advisors reduced its Merck (MRK) stake by 4.9% in Q1 2026, selling an estimated $1.73M and leaving 292,328 shares worth $35.2M. The position accounts for 0.64% of the portfolio, ranked #36.

Douglass Winthrop Advisors first reported a position in MRK in Q2 2013 and has held it in 52 quarters since. The position peaked at $111M in Q1 2021. 3,778 funds tracked by Wall St. Rank hold MRK as of Q1 2026.

  • Douglass Winthrop Advisors held 292,328 shares of Merck worth $35.2M as of Q1 2026.
  • Douglass Winthrop Advisors sold 15,002 Merck shares in Q1 2026, an estimated $1.73M.
  • Merck made up 0.64% of Douglass Winthrop Advisors's portfolio in Q1 2026, its #36 holding.
  • Douglass Winthrop Advisors first reported a position in Merck in Q2 2013 and has held it in 52 quarters since.
  • Douglass Winthrop Advisors's Merck position peaked at $111M in Q1 2021.
  • 3,778 funds tracked by Wall St. Rank held Merck as of Q1 2026.

Based on Douglass Winthrop Advisors's 13F filing for Q1 2026, filed 14 May 2026.